Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
IFAG AG
With
Hiscia Society for Cancer Research
IFAG Basel AG, both Switzerland
see summary
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of pancreatic cancer, adenocarcinoma, UICC stage II-IV
Age between 18 (Austria: 19) and 85 years
No previous malign tumor
ECOG 0-2
Estimated life expectancy \> 3 months
Surgical resection of the tumor (R0, R1) or determination of interoperability
Conventional oncological therapy and measurements, or passive after-care ("best care")
Follow-up for several years feasible
Patient gives written consent to use the anonymized date for evaluation
You may not be if
Other Iscador® sorts than Qu in the test group
Other mistletoe preparations in the test group
Any mistletoe preparation in the control group
Non-oncological immunomodulating, -stimulating or -suppressive drugs (e.g. Echinacea, interferons, Polyerga®, BCG, azathioprine). Allowed are approved tumor inhibiting immuno- or targeted therapies (e.g. bevacizumab, cetuximab) and tumor specific vaccines
HIV infection, Aids, organ transplantation
Contraindications for Iscador® Qu (allergy against mistletoe, acute inflammatory disease or fever \> 38.5°C, active tuberculosis, hyperthyreosis with not-adjusted metabolism, primary brain or spinal tumor, brain metastases)
Patients participating in another clinical study with non-approved substances
Clareo Health | Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)
